Abstract:Background: Undergoing solid organ transplantation (SOT) exposes the recipient to various infectious risks, including possible transmission of pathogen by the transplanted organ, post-surgical infections, reactivation of latent pathogens, or novel infections. Recent advances: In the last few years, the emergence of Zika virus has raised concerns in the transplant community. Few cases have been described in SOT patients, and these were associated mainly with moderate disease and favorable outcome; the notable exception is a recent case of fatal meningo-encephalopathy in a heart transplant recipient. Because of the advances in treating hepatitis C, several teams recently started to use organs from hepatitis C-positive donors. The worldwide increasing incidence of multidrug-resistant pathogens, as well as the increasing incidence of Clostridioidesdifficile infection, is of particular concern in SOT patients. In the field of mycology, the main recent therapeutic advance is the availability of isavuconazole for the treatment of invasive aspergillosis and mucormycosis. This drug has the advantage of minimal interaction with calcineurin inhibitors. Regarding the viral reactivations occurring after transplant, cytomegalovirus (CMV) infection is still a significant issue in SOT patients. The management of resistant CMV remains particularly difficult. The approval of letermovir, albeit in bone marrow transplantation, and the therapeutic trial of maribavir bring a ray of hope. Another advancement in management of post-transplant infections is the development of in vitro tests evaluating pathogen-specific immune response, such as immunodiagnostics for CMV and, more recently, tests for monitoring immunity against BK virus. Conclusion: The increasing number of organ transplantations, the use of newer immunosuppressive drugs, and high-risk donors continue to define the landscape of transplant infectious diseases in the current era.

Recent advances in cytomegalovirus infection management in solid organ transplant recipients

What's New: Updates on Cytomegalovirus in Solid Organ Transplantation

Progress on the association between human gene polymorphisms and cytomegalovirus infection after transplantation

Current and future strategies for the prevention and treatment of cytomegalovirus infections in transplantation

Cytomegalovirus Treatment in Solid Organ Transplantation: An Update on Current Approaches

Pathogen-specific cell-mediated immunity to guide the management of cytomegalovirus in solid organ transplantation: state of the art clinical review

Emerging concepts of CMV in transplantation

Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice

Cytomegalovirus Infection After Solid Organ Transplantation: How I Use Cell-Mediated Immune Assays for Management

Recent advances in understanding and managing infectious diseases in solid organ transplant recipients

Updates on antiviral drugs for cytomegalovirus prevention and treatment

New Developments in the Management of Cytomegalovirus Infection After Transplantation

Prevention and therapy of viral infections in patients with solid organ transplantation

Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update

Cytomegalovirus Retinitis in the Modern Era of Solid Organ Transplantation

Management of resistant and refractory cytomegalovirus infections after transplantation

Management of cytomegalovirus infection after liver transplantation

Cytomegalovirus infection in liver transplant recipients: updates on clinical management

Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update

Advancing cytomegalovirus prevention in solid organ transplant recipients: The promise of cell‐mediated immune assays

Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data